Monthly Prescribing Reference

Invega Hafyera Approved for Twice-Yearly Treatment of Schizophrenia

The Food and Drug Administration has approved Invega Hafyera ™ (paliperidone palmitate), an every 6-month injection, for the treatment of schizophrenia in adults. Invega Hafyera is a long-acting ...
FiercePharma

New Data on INVEGA(R) SUSTENNA(R) and RISPERDAL(R) CONSTA(R) for Schizophrenia to be Presented at Major Psychiatry Meeting

TITUSVILLE, N.J., May 24 /PRNewswire/ --New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone ...
Nasdaq

FDA OK's Janssen Pharmaceutical's INVEGA HAFYERA To Treat Adults With Schizophrenia - Quick Facts

(RTTNews) - Janssen Pharmaceutical, Inc., wholly-owned by Johnson & Johnson (JNJ), announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic ...
FierceBiotech

INVEGA(R) Approved as First and Only Antipsychotic Treatment for Schizoaffective Disorder in the European Union

BEERSE, Belgium, January 4, 2011 /PRNewswire/ -- Janssen-Cilag International NV today announced that it has received approval from the European Commission for the first antipsychotic treatment for ...
Medindia

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA™ (6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia

INVEGA HAFYERA™ offers patients the fewest doses per year for a life less defined by schizophrenia medication Click-to-Tweet: #BREAKINGNEWS the @US_FDA approved new long-acting injectable treatment ...
pharmaphorum

FDA clears J&J's twice-yearly Invega for schizophrenia

One of the biggest challenges to treating schizophrenia is non-compliance with treatment, but Johnson & Johnson's pharma unit Janssen is trumpeting a new version of its Invega drug that could solve ...
PharmaTimes

J&J’s schizophrenia drug Invega gets thumbs-up from EU

Johnson & Johnson’s Janssen-Cilag has been given the go-ahead by regulators in Europe to sell Invega, the follow-up to its schizophrenia blockbuster Risperdal. Johnson & Johnson’s Janssen-Cilag has ...
Medindia

INVEGA(TM) Gets Marketing Authority from EU to Treat Schizophrenia

TITUSVILLE, N.J., The European Commission granted marketing authorization for INVEGA(TM) (paliperidone prolonged release tablets), an atypical antipsychotic medication for the treatment of ...
Monthly Prescribing Reference

Invega Gains Indication for Schizophrenia in Adolescents

The FDA has approved Invega (paliperidone extended-release tablets; Janssen) for the treatment of schizophrenia in adolescents 12–17 years of age. This approval was based on data from a six-week ...
Nasdaq

J&J (JNJ) Gets FDA Nod for Twice-Yearly Schizophrenia Drug

Johnson & Johnson JNJ announced that the FDA has approved another long-acting formulation of its antipsychotic drug, paliperidone palmitate, Invega Hafyera, for treating schizophrenia in adults.
FierceBiotech

J&J trumpets early success for 3-month Invega Sustenna PhIII schizophrenia trial

Johnson & Johnson wrapped a Phase III study of a 3-month formulation of Invega Sustenna early after an independent monitoring group called it on positive efficacy ...
Business Insider

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA™ (6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia

TITUSVILLE, N.J., Sept. 1, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical ...